Publications by authors named "John B Warren"

Claim this Profile
H
High-Dose Statins Increase Adverse Events and Do Not Improve Survival.
Simon B Dimmitt, Hans G Stampfer, John B Warren, Jennifer H Martin

J Am Coll Cardiol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The trouble with antidepressants: why the evidence overplays benefits and underplays risks-an essay by John B Warren.
John B Warren

BMJ· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small Increase in Mortality With High Dose, But Not Low Dose, Statin.
Simon B Dimmitt, John B Warren, Hans G Stampfer

J Am Coll Cardiol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translating the dose response into risk and benefit.
John B Warren

Br J Clin Pharmacol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unbalanced risk-benefit analysis of ADHD drugs.
John B Warren

Lancet Psychiatry· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacodynamic and clinical trial evidence for statin dose.
Simon B Dimmitt, Hans G Stampfer, John B Warren

Br J Clin Pharmacol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opioids out of control.
Christopher N Floyd, John B Warren

Br J Clin Pharmacol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fatal prescription charts.
John B Warren

Br J Clin Pharmacol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical benefits of evolocumab appear less than hoped.
Simon B Dimmitt, Hans G Stampfer, Jennifer H Martin, John B Warren

Lancet· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Composite endpoints and the distortion of risk-benefit analysis.
John B Warren

Br J Clin Pharmacol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trading Lower HbA1c for Increased Adverse Events: A Zero Sum Game?
Simon B Dimmitt, John B Warren, Jennifer H Martin, Hans G Stampfer

J Am Coll Cardiol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cholesterol trials and mortality.
John B Warren, Simon B Dimmitt, Hans G Stampfer

Br J Clin Pharmacol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common statin side effects explain poor compliance.
Simon B Dimmitt, Hans G Stampfer, John B Warren

Br J Clin Pharmacol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin dose based on limited evidence.
Simon B Dimmitt, Hans G Stampfer, Alicia Moran, Marianne Scartozzi, John B Warren

J Am Coll Cardiol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
β-adrenoceptor blockers valuable but higher doses not necessary.
Simon B Dimmitt, Hans G Stampfer, John B Warren

Br J Clin Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?
John B Warren

Br J Clin Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symmetrical analysis of risk-benefit.
John B Warren, Simon Day, Peter Feldschreiber

Br J Clin Pharmacol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antidepressants and the developing nervous system.
John B Warren

Br J Clin Pharmacol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on: Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe by Johnston et al.
John B Warren, Kersti Oselin

Br J Clin Pharmacol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-dimensional hard x-ray field retrieval using a moveable structure.
Manuel Guizar-Sicairos, Kenneth Evans-Lutterodt, Abdel F Isakovic, Aaron Stein, John B Warren

Opt Express· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precaution, cyclooxygenase inhibition, and cardiovascular risk.
James M Ritter, Idris Harding, John B Warren

Trends Pharmacol Sci· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single walled carbon nanotube reactivity and cytotoxicity following extended aqueous exposure.
Barbara J Panessa-Warren, Mathew M Maye, John B Warren, Kenya M Crosson

Environ Pollut· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The exosporium of B. cereus contains a binding site for gC1qR/p33: implication in spore attachment and/or entry.
Berhane Ghebrehiwet, Lee Tantral, Mathew A Titmus, Barbara J Panessa-Warren, George T Tortora, John B Warren

Adv Exp Med Biol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High resolution FESEM and TEM reveal bacterial spore attachment.
Barbara J Panessa-Warren, George T Tortora, John B Warren

Microsc Microanal· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis